Affini-T Therapeutics

Veja o organograma con seus 12 executivos principais

Biografias mais buscadas da Affini-T Therapeutics

• Jak Knowles, Co-Founder, President, Chief Executive Officer and Di...
• Lucio Iannone, Director
• Arjun Goyal, Director

Recentes movimentos de executivos em Affini-T Therapeutics

• Kathy Bergsteinsson, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 14 de novembro de 2023).

Criar um alerta
para seguir os movimentos de executivos da Affini-T Therapeutics.

Affini-T Therapeutics possui 2.277 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnologia

• Histogen has filed for bankruptcy protection  (publicado em 19 de abril de 2024).
• Bruker has announced the acquisition of NanoString Technologies  (publicado em 18 de abril de 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (publicado em 16 de abril de 2024).

Outros contatos sugeridos na indústria do Biotecnologia

• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics
• Vik Bajaj - Director da Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board da Sensorion

Saiba mais sobre a indústria do Biotecnologia >

Últimos comunicados de imprensa de Affini-T Therapeutics

• Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Affini-T Therapeutics
• Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting | Affini-T Therapeutics
• Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Affini-T Therapeutics
• Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer | Affini-T Therapeutics
• Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Affini-T Therapeutics
• Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
• Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
• A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
• View more press releases Close

Redes sociais sobre Affini-T Therapeutics

• Affini-T Therapeutics na Wikipedia, Google News e Yahoo Finance
• Affini-T Therapeutics na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Jak Knowles

Ligue para a Affini-T Therapeutics em +1 619...

Veja o organograma

Register to receive your alert

Relatório um erro